VEGF-121 is one of the several isoforms of VEGF-A, generated through alternative splicing of the VEGF gene. It is composed of 121 amino acids and is known for its ability to stimulate the proliferation and survival of endothelial cells, which line the interior surface of blood vessels . Unlike some other VEGF isoforms, VEGF-121 lacks heparin-binding domains, which affects its interaction with the extracellular matrix and its bioavailability.
Recombinant VEGF-121 is often produced in bacterial systems such as Escherichia coli (E. coli). The recombinant protein is typically tagged with a His-tag to facilitate purification through affinity chromatography. This method ensures high purity and activity of the protein, making it suitable for various research and therapeutic applications .
VEGF-121 plays a crucial role in:
Due to its significant role in angiogenesis, VEGF-121 is extensively studied in the context of cancer research. Tumors often exploit VEGF to promote blood vessel formation, ensuring a sufficient supply of nutrients and oxygen for their growth. Inhibiting VEGF activity is a therapeutic strategy in cancer treatment, aiming to starve the tumor by cutting off its blood supply .
Additionally, VEGF-121 is used in research to study various aspects of vascular biology, including the mechanisms of blood vessel formation, the effects of hypoxia (low oxygen conditions), and the response of endothelial cells to different stimuli .